<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387450</url>
  </required_header>
  <id_info>
    <org_study_id>Ongoing recording</org_study_id>
    <nct_id>NCT02387450</nct_id>
  </id_info>
  <brief_title>Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication</brief_title>
  <official_title>Reduction de la Morbi-mortalité Cardiovasculaire Chez l'artériopathe Claudicant Par le Sildenafil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sildenafil has shown potential effects both on vasodilator mechanisms and as an inhibitor of
      the NO/GMPc Pain activation. The investigators aim at estimating the benefit of sildenafil in
      term of morbi-mortality in patients with arterial claudication on a multicenter prospective
      double blind study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will ask to participate after oral and written information. Evaluation of
      walking capacity (self reported and treadmill measured), co-morbid condition and quality of
      life (WELCH, SF-36, Edinburg) will be performed at inclusion, after the first dose and at 3
      months of oral treatment through sildenafil 100mg/day or placebo from inclusion to 3 months.

      Indication for revascularisation will be evaluated at 3 months according to symptoms and
      walking capacity according to the Rutherford classification.

      Primary endpoint is the proportion of patients showing either a fatal events (cardio-vascular
      or noncardiovascular) or hospitalisation for non fatal cardiovascular events at 6 and 9
      months follow up from inclusion.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morbi-mortality : combined criterion (Cardiovascular fatal and non fatal event Improvement of 1 stage)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life Questionnaire</measure>
    <time_frame>3, 6 and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and secondary effects (Headache, Hypotension) (Proportion of Participants with Adverse Event)</measure>
    <time_frame>3, 6 and 9 months</time_frame>
    <description>Proportion of Participants with Adverse Events (sildenafil vs. placebo)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking capacity (treadmill test)</measure>
    <time_frame>3, 6 and 9 months</time_frame>
    <description>treadmill test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of revascularized patients</measure>
    <time_frame>6 and 9 months</time_frame>
    <description>Revascularisation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Treated group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil, oral, 100mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>100 mg per day</description>
    <arm_group_label>Treated group</arm_group_label>
    <other_name>Viagra or revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with same presentation as the active drug</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ABI&lt;0.90

          -  Vascular type claudication

          -  stable walking impairment for at least 3 months

          -  Optimal cardiovasc treatment (Anti-platelet, HMGCoA-Inh, ACE-Inh or AT2 inh)

          -  Age &gt; 30 years

        Exclusion Criteria:

          -  Refuse to participate

          -  Administrative protection

          -  Severe renal (clearance &lt; 30 ml/min) or hepatic (Child-Pugh C) failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>pierre Abraham, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital in Angers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>pierre ABRAHAM, MD, PhD</last_name>
    <phone>+33 241353689</phone>
    <email>piabraham@chu-angers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier universitaire</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Claudication</keyword>
  <keyword>Maximal walking distance</keyword>
  <keyword>Morbi-mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

